Who are Mesalazine(asacol 800 mg)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MMX Mesalamine, MMX mesalamine/ mesalazine, sulphasalazine (SSZ), Asacol (mesalamine), Granulated mesalamine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mesalazine-asacol-800-mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Mesalazine(asacol 800 mg) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mesalazine(asacol 800 mg) (Mesalazine(asacol 800 mg)) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-aminosalicylic acid (5-ASA) agent. Area: Gastroenterology.

marketed 5-aminosalicylic acid (5-ASA) agent Prostaglandin and leukotriene synthesis; nuclear factor-kappa B (NF-κB) pathway Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Mesalazine(asacol 800 mg) (Mesalazine(asacol 800 mg)) — Tehran University of Medical Sciences. Mesalazine reduces intestinal inflammation by inhibiting prostaglandin and leukotriene production in the colon.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Mesalazine(asacol 800 mg) TARGET	Mesalazine(asacol 800 mg)	Tehran University of Medical Sciences	marketed	5-aminosalicylic acid (5-ASA) agent	Prostaglandin and leukotriene synthesis; nuclear factor-kappa B (NF-κB) pathway
MMX Mesalamine	MMX Mesalamine	Shire	marketed	5-aminosalicylic acid (5-ASA) agent	Prostaglandin and leukotriene pathways (topical anti-inflammatory)
MMX mesalamine/ mesalazine	MMX mesalamine/ mesalazine	Shire	marketed	5-aminosalicylic acid (5-ASA) agent	Prostaglandin and leukotriene synthesis; non-selective anti-inflammatory mechanism
sulphasalazine (SSZ)	sulphasalazine (SSZ)	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	5-aminosalicylic acid (5-ASA) agent	Prostaglandin and leukotriene synthesis inhibition; NF-κB pathway modulation
Asacol (mesalamine)	Asacol (mesalamine)	University of Washington	marketed	5-aminosalicylic acid (5-ASA) agent	Prostaglandin and leukotriene synthesis inhibition; free radical scavenging
Granulated mesalamine	Granulated mesalamine	Bausch Health Americas, Inc.	phase 3	5-aminosalicylic acid (5-ASA) agent	Prostaglandin and leukotriene synthesis inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-aminosalicylic acid (5-ASA) agent class)

Shire · 2 drugs in this class
Bausch Health Americas, Inc. · 1 drug in this class
Tehran University of Medical Sciences · 1 drug in this class
University of Washington · 1 drug in this class
Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mesalazine(asacol 800 mg) — Competitive Intelligence Brief. https://druglandscape.com/ci/mesalazine-asacol-800-mg. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab